Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001213900-25-073648
Filing Date
2025-08-08
Accepted
2025-08-08 16:05:48
Documents
16
Effectiveness Date
2025-08-08

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea025141402-s8_niagen.htm S-8 64876
2 OPINION OF PROSKAUER ROSE LLP ea025141402ex5-1_niagen.htm EX-5.1 10534
3 CONSENT OF CROWE LLP ea025141402ex23-1_niagen.htm EX-23.1 1894
4 CONSENT OF MARCUM LLP ea025141402ex23-2_niagen.htm EX-23.2 1610
5 FILING FEE TABLE ea025141402ex-fee_niagen.htm   iXBRL EX-FILING FEES 13695
6 GRAPHIC ex5-1_001.jpg GRAPHIC 2345
  Complete submission text file 0001213900-25-073648.txt   214407

Data Files

Seq Description Document Type Size
19 EXTRACTED XBRL INSTANCE DOCUMENT ea025141402ex-fee_niagen_htm.xml XML 4818
Mailing Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024
Business Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024 310-388-6706
Niagen Bioscience, Inc. (Filer) CIK: 0001386570 (see all company filings)

EIN.: 262940963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-289418 | Film No.: 251198374
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)